Neostigmine/glycopyrronium bromide

Neostigmine/glycopyrronium bromide
Combination of
Neostigmine	Cholinesterase inhibitor
Glycopyrronium bromide	Antimuscarinic agent
Clinical data
Trade names	Prevduo
Other names	Neostigmine methylsulfate/glycopyrrolate, glycopyrronium bromide/neostigmine metilsulfate
License data	US DailyMed: Neostigmine methylsulfate and glycopyrrolate;
Routes of; administration	Intravenous
ATC code	N07AA51 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;

Neostigmine/glycopyrronium bromide, sold under the brand name Prevduo , is a fixed-dose combination medication used for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.^[2] It contains neostigmine as the methylsulfate, a cholinesterase inhibitor, and glycopyrronium bromide, an antimuscarinic agent.^[2]

Neostigmine/glycopyrronium bromide was approved for medical use in the United Kingdom in 2007,^[1] and in the United States in February 2023.^[3]

Medical uses

Neostigmine/glycopyrronium bromide is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following non-depolarizing neuromuscular blocking agent reversal administration.^[3]

References

^ ^a ^b "Glycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml Solution for Injection - Summary of Product Characteristics (SmPC)". (emc). 12 November 2018. Archived from the original on 7 August 2022. Retrieved 25 February 2023.
^ ^a ^b ^c "Archived copy" (PDF). Archived (PDF) from the original on 26 February 2023. Retrieved 25 February 2023.{{cite web}}: CS1 maint: archived copy as title (link)
^ ^a ^b https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216903Orig1s000ltr.pdf Archived 26 February 2023 at the Wayback Machine This article incorporates text from this source, which is in the public domain.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Glycopyrronium_Bromide_and_Neostigmine_Metilsulfate_SmPC-1] "Glycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml Solution for Injection - Summary of Product Characteristics (SmPC)". (emc). 12 November 2018. Archived from the original on 7 August 2022. Retrieved 25 February 2023.

[Prevduo_FDA_label-2] "Archived copy" (PDF). Archived (PDF) from the original on 26 February 2023. Retrieved 25 February 2023.{{cite web}}: CS1 maint: archived copy as title (link)

[Prevduo_approval_letter-3] ttps://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216903Orig1s000ltr.pdf Archived 26 February 2023 at the Wayback Machine This article incorporates text from this source, which is in the public domain.

[1]

[2]

[3]